X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES SHASUN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES SHASUN LTD CIPLA/
STRIDES SHASUN LTD
 
P/E (TTM) x 45.7 13.7 332.9% View Chart
P/BV x 3.9 1.6 246.3% View Chart
Dividend Yield % 0.3 0.6 52.6%  

Financials

 CIPLA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
STRIDES SHASUN LTD
Mar-17
CIPLA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6221,275 48.8%   
Low Rs458918 49.9%   
Sales per share (Unadj.) Rs181.9389.6 46.7%  
Earnings per share (Unadj.) Rs12.928.0 46.0%  
Cash flow per share (Unadj.) Rs29.348.9 60.0%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.40.4 90.2%  
Book value per share (Unadj.) Rs155.7303.1 51.4%  
Shares outstanding (eoy) m804.5189.42 899.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.8 105.5%   
Avg P/E ratio x42.039.2 107.1%  
P/CF ratio (eoy) x18.422.4 82.2%  
Price / Book Value ratio x3.53.6 95.9%  
Dividend payout %15.516.1 96.6%   
Avg Mkt Cap Rs m434,51698,036 443.2%   
No. of employees `00023.05.8 397.3%   
Total wages/salary Rs m26,3385,881 447.8%   
Avg. sales/employee Rs Th6,349.16,005.9 105.7%   
Avg. wages/employee Rs Th1,143.01,014.0 112.7%   
Avg. net profit/employee Rs Th449.3431.2 104.2%   
INCOME DATA
Net Sales Rs m146,30234,834 420.0%  
Other income Rs m2,2871,686 135.7%   
Total revenues Rs m148,58936,520 406.9%   
Gross profit Rs m24,7586,428 385.2%  
Depreciation Rs m13,2291,872 706.9%   
Interest Rs m1,5942,269 70.2%   
Profit before tax Rs m12,2223,973 307.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-704 -1,941.7%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,798470 382.5%   
Profit after tax Rs m10,3542,501 414.0%  
Gross profit margin %16.918.5 91.7%  
Effective tax rate %14.711.8 124.3%   
Net profit margin %7.17.2 98.6%  
BALANCE SHEET DATA
Current assets Rs m87,37038,165 228.9%   
Current liabilities Rs m33,08130,402 108.8%   
Net working cap to sales %37.122.3 166.5%  
Current ratio x2.61.3 210.4%  
Inventory Days Days8777 112.4%  
Debtors Days Days62104 59.6%  
Net fixed assets Rs m111,56737,639 296.4%   
Share capital Rs m1,609894 179.9%   
"Free" reserves Rs m123,64526,210 471.7%   
Net worth Rs m125,25427,105 462.1%   
Long term debt Rs m36,45416,377 222.6%   
Total assets Rs m209,53281,168 258.1%  
Interest coverage x8.72.8 315.1%   
Debt to equity ratio x0.30.6 48.2%  
Sales to assets ratio x0.70.4 162.7%   
Return on assets %5.75.9 97.0%  
Return on equity %8.39.2 89.6%  
Return on capital %8.512.1 70.5%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06613,465 379.2%   
Fx outflow Rs m17,6784,076 433.7%   
Net fx Rs m33,3889,389 355.6%   
CASH FLOW
From Operations Rs m23,8242,881 826.8%  
From Investments Rs m-13,127-7,051 186.2%  
From Financial Activity Rs m-13,2393,382 -391.4%  
Net Cashflow Rs m-2,478-788 314.6%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS